Constantin Theodore Yiannoutsos

List of Publications by Year
in descending order

141 papers	7,710 citations	50276 46 h-index	53230 85 g-index
142 all docs	142 docs citations	142 times ranked	8577 citing authors

#	Article	IF	Citations
1	Virologic non‑suppression and early loss to follow up among pregnant and non‑pregnant adolescents aged 15–19 years initiating antiretroviral therapy in South Africa: a retrospective cohort study. Journal of the International AIDS Society, 2022, 25, e25870.	3.0	7
2	Successive Wave Analysis to Assess Nonresponse Bias in a Statewide Random Sample Testing Study for SARS-CoV-2. Journal of Public Health Management and Practice, 2022, 28, E685-E691.	1.4	2
3	Delayed presentation of HIV among older individuals: a growing problem. Lancet HIV,the, 2022, 9, e269-e280.	4.7	26
4	Factors that differentiate COVID-19 vaccine intentions among Indiana parents: Implications for targeted vaccine promotion. Preventive Medicine, 2022, 158, 107023.	3.4	11
5	Retention in care and viral suppression in the PMTCT continuum at a large referral facility in western Kenya. AIDS and Behavior, 2022, , 1.	2.7	0
6	Infection Fatality Ratios for COVID-19 Among Noninstitutionalized Persons 12 and Older: Results of a Random-Sample Prevalence Study. Annals of Internal Medicine, 2021, 174, 135-136.	3.9	31
7	Bayesian estimation of SARS-CoV-2 prevalence in Indiana by random testing. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	16
8	Virologic response of adolescents living with perinatally acquired HIV receiving antiretroviral therapy in the period of early adolescence (10–14 years) in South Africa. Aids, 2021, 35, 971-978.	2.2	0
9	How Many SARS-CoV-2–Infected People Require Hospitalization? Using Random Sample Testing to Better Inform Preparedness Efforts. Journal of Public Health Management and Practice, 2021, 27, 246-250.	1.4	38
10	Symptoms and symptom clusters associated with SARS-CoV-2 infection in community-based populations: Results from a statewide epidemiological study. PLoS ONE, 2021, 16, e0241875.	2.5	56
11	Effects of National Adoption of Treat-All Guidelines on Pre-Antiretroviral Therapy (ART) CD4 Testing and Viral Load Monitoring After ART initiation: A Regression Discontinuity Analysis. Clinical Infectious Diseases, 2021, 73, e1273-e1281.	5.8	15
12	Outcomes of retained and disengaged pregnant women living with HIV in Uganda. PLoS ONE, 2021, 16, e0251413.	2.5	4
13	Compartmentalization of cerebrospinal fluid inflammation across the spectrum of untreated HIV-1 infection, central nervous system injury and viral suppression. PLoS ONE, 2021, 16, e0250987.	2.5	30
14	Pregnancies among women living with HIV using contraceptives and antiretroviral therapy in western Kenya: a retrospective, cohort study. BMC Medicine, 2021, 19, 178.	5.5	4
15	Global HIV mortality trends among children on antiretroviral treatment corrected for under‑reported deaths: an updated analysis of the International epidemiology Databases to Evaluate AIDS collaboration. Journal of the International AIDS Society, 2021, 24, e25780.	3.0	5
16	Achieving consistency in measures of HIV‑1 viral suppression across countries: derivation of an adjustment based on international antiretroviral treatment cohort data. Journal of the International AIDS Society, 2021, 24, e25776.	3.0	2
17	Contemporary Outcomes of Distal Lower Extremity Bypass for Chronic Limb-Threatening Ischemia and A Model-Based Comparison With Autologous Bone Marrow-Derived Cell Therapy for Limb Preservation. Journal of Vascular Surgery, 2021, 74, e374-e375.	1.1	0
18	Semiparametric regression on cumulative incidence function with interval-censored competing risks data and missing event types. Biostatistics, 2021, , .	1.5	1

#	Article	IF	Citations
19	A qualitative study of the barriers and enhancers to retention in care for pregnant and postpartum women living with HIV. PLOS Global Public Health, 2021, 1, e0000004.	1.6	5
20	Global estimates of viral suppression in children and adolescents and adults on antiretroviral therapy adjusted for missing viral load measurements: a multiregional, retrospective cohort study in 31 countries. Lancet HIV,the, 2021, 8, e766-e775.	4.7	38
21	FIRST- LINE ANTIRETROVIRAL TREATMENT FAILURE IN EAST AFRICAN CHILDREN.. East African Medical Journal, 2021, 98, 4082-4092.	0.0	0
22	Deductive Semiparametric Estimation in Double-Sampling Designs with Application to PEPFAR. Statistics in Biosciences, 2020, 12, 417-445.	1.2	1
23	PS-SiZer map to investigate significant features of body-weight profile changes in HIV infected patients in the IeDEA Collaboration. PLoS ONE, 2020, 15, e0220165.	2.5	0
24	Weight-for-age distributions among children with HIV on antiretroviral therapy in the International epidemiology Databases to Evaluate AIDS (IeDEA) multiregional consortium. BMC Research Notes, 2020, 13, 249.	1.4	3
25	A pseudo‐likelihood method for estimating misclassification probabilities in competing‐risks settings when true‐event data are partially observed. Biometrical Journal, 2020, 62, 1747-1768.	1.0	0
26	Mortality Among People With HIV Treated for Tuberculosis Based on Positive, Negative, or No Bacteriologic Test Results for Tuberculosis: The IeDEA Consortium. Open Forum Infectious Diseases, 2020, 7, ofaa006.	0.9	2
27	Semiparametric regression and risk prediction with competing risks data under missing cause of failure. Lifetime Data Analysis, 2020, 26, 659-684.	0.9	8
28	Lower rates of ART initiation and decreased retention among ART-naïve patients who consume alcohol enrolling in HIV care and treatment programs in Kenya and Uganda. PLoS ONE, 2020, 15, e0240654.	2.5	6
29	Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample â€" Indiana, April 25â€"29, 2020. Morbidity and Mortality Weekly Report, 2020, 69, 960-964.	15.1	162
30	A semiparametric method for the analysis of outcomes during a gap in HIV care under incomplete outcome ascertainment. Statistical Communications in Infectious Diseases, 2020, 12, .	0.2	0
31	Title is missing!. , 2020, 15, e0220165.		0
32	Title is missing!. , 2020, 15, e0220165.		0
33	Title is missing!. , 2020, 15, e0220165.		0
34	Title is missing!. , 2020, 15, e0220165.		0
35	Title is missing!. , 2020, 15, e0220165.		0
36	Title is missing!. , 2020, 15, e0220165.		0

#	ARTICLE	IF	CITATIONS
37	Title is missing!. , 2020, 15, e0240654.		0
38	Title is missing!. , 2020, 15, e0240654.		0
39	Title is missing!. , 2020, 15, e0240654.		0
40	Title is missing!. , 2020, 15, e0240654.		0
41	Title is missing!. , 2020, 15, e0240654.		0
42	Title is missing!. , 2020, 15, e0240654.		0
43	Title is missing!. , 2020, 15, e0240654.		0
44	Title is missing!. , 2020, 15, e0240654.		0
45	Implementation of â€œTreatâ€allâ€at adult <scp>HIV</scp> care and treatment sites in the Global Ie<scp>DEA</scp> Consortium: results from the Site Assessment Survey. Journal of the International AIDS Society, 2019, 22, e25331.	3.0	32
46	Nonparametric estimation of the cumulative incidence function under outcome misclassification using external validation data. Statistics in Medicine, 2019, 38, 5512-5527.	1.6	2
47	Increasing body mass index or weight does not appear to influence the association between efavirenz-based antiretroviral therapy and implant effectiveness among HIV-positive women in western Kenya. Contraception, 2019, 100, 288-295.	1.5	2
48	Diagnosis and clinical outcomes of extrapulmonary tuberculosis in antiretroviral therapy programmes in lowâ€and middleâ€income countries: a multicohort study. Journal of the International AIDS Society, 2019, 22, e25392.	3.0	24
49	Research priorities to inform â€œTreat Allâ€policy implementation for people living with <scp>HIV</scp> in subâ€Saharan Africa: a consensus statement from the International epidemiology Databases to Evaluate <scp>AIDS</scp> (Ie<scp>DEA</scp>). Journal of the International AIDS Society, 2019, 22, e25218.	3.0	32
50	Changes in rapid HIV treatment initiation after national â€œtreat allâ€policy adoption in 6 sub-Saharan African countries: Regression discontinuity analysis. PLoS Medicine, 2019, 16, e1002822.	8.4	53
51	Semiparametric competing risks regression under interval censoring using the R package intccr. Computer Methods and Programs in Biomedicine, 2019, 173, 167-176.	4.7	8
52	Updates to the Spectrum/AIM model for estimating key HIV indicators at national and subnational levels. Aids, 2019, 33, S227-S234.	2.2	52
53	Global variations in mortality in adults after initiating antiretroviral treatment. Aids, 2019, 33, S283-S294.	2.2	16
54	Nonparametric Inference for Markov Processes with Missing Absorbing State. Statistica Sinica, 2019, 29, 2083-2104.	0.3	9

#	Article	IF	Citations
55	Diagnostic and Prognostic Value of JC Virus DNA in Plasma in Progressive Multifocal Leukoencephalopathy. Clinical Infectious Diseases, 2018, 67, 65-72.	5.8	12
56	Adolescent pregnancy at antiretroviral therapy (<scp>ART</scp>) initiation: a critical barrier to retention on <scp>ART</scp>. Journal of the International AIDS Society, 2018, 21, e25178.	3.0	16
57	A Phase II Study of Pemetrexed in Patients with Recurrent Thymoma and Thymic Carcinoma. Journal of Thoracic Oncology, 2018, 13, 1940-1948.	1.1	39
58	Access to antiretroviral therapy in HIV-infected children aged 0–19 years in the International Epidemiology Databases to Evaluate AIDS (IeDEA) Global Cohort Consortium, 2004–2015: A prospective cohort study. PLoS Medicine, 2018, 15, e1002565.	8.4	33
59	Increased prevalence of pregnancy and comparative risk of program attrition among individuals starting HIV treatment in East Africa. PLoS ONE, 2018, 13, e0190828.	2.5	6
60	HIV treatment eligibility expansion and timely antiretroviral treatment initiation following enrollment in HIV care: A metaregression analysis of programmatic data from 22 countries. PLoS Medicine, 2018, 15, e1002534.	8.4	38
61	Adherence to antiretroviral therapy in a clinical cohort of HIV-infected children in East Africa. PLoS ONE, 2018, 13, e0191848.	2.5	21
62	The Causal Effect of Tracing by Peer Health Workers on Return to Clinic Among Patients Who Were Lost to Follow-up From Antiretroviral Therapy in Eastern Africa: A "Natural Experiment" Arising From Surveillance of Lost Patients. Clinical Infectious Diseases, 2017, 64, 1547-1554.	5.8	20
63	Semiparametric regression on cumulative incidence function with interval‐censored competing risks data. Statistics in Medicine, 2017, 36, 3683-3707.	1.6	17
64	Reply. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, e56-e57.	2.1	0
65	Assessment of risk behaviors in patients with opioid prescriptions: A study of indiana's inspect data. American Journal on Addictions, 2017, 26, 822-829.	1.4	5
66	Observational Study of the Effect of Patient Outreach on Return to Care: The Earlier the Better. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 141-148.	2.1	11
67	Evaluating the Impact of a HIV Low-Risk Express Care Task-Shifting Program: A Case Study of the Targeted Learning Roadmap. Epidemiologic Methods, 2016, 5, 69-91.	0.9	13
68	Retention in Care and Patient-Reported Reasons for Undocumented Transfer or Stopping Care Among HIV-Infected Patients on Antiretroviral Therapy in Eastern Africa: Application of a Sampling-Based Approach. Clinical Infectious Diseases, 2016, 62, 935-944.	5.8	137
69	Facility-Level Factors Influencing Retention of Patients in HIV Care in East Africa. PLoS ONE, 2016, 11, e0159994.	2.5	49
70	Determinants of Weight Evolution Among HIV-Positive Patients Initiating Antiretroviral Treatment in Low-Resource Settings. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 70, 146-154.	2.1	15
71	Impact of and Correction for Outcome Misclassification in Cumulative Incidence Estimation. PLoS ONE, 2015, 10, e0137454.	2.5	16
72	Estimation of mortality among HIV-infected people on antiretroviral treatment in east Africa: a sampling based approach in an observational, multisite, cohort study. Lancet HIV,the, 2015, 2, e107-e116.	4.7	80

#	ARTICLE	IF	CITATIONS
73	Marginal and Conditional Distribution Estimation from Double‐sampled Semi‐competing Risks Data. Scandinavian Journal of Statistics, 2015, 42, 87-103.	1.4	2
74	Cerebrospinal Fluid (CSF) Neuronal Biomarkers across the Spectrum of HIV Infection: Hierarchy of Injury and Detection. PLoS ONE, 2014, 9, e116081.	2.5	95
75	CD4 trajectory adjusting for dropout among HIV‐positive patients receiving combination antiretroviral therapy in an East African HIV care centre. Journal of the International AIDS Society, 2014, 17, 18957.	3.0	8
76	Choosing profile double‐sampling designs for survival estimation with application to President's Emergency Plan for AIDS Relief evaluation. Statistics in Medicine, 2014, 33, 2017-2029.	1.6	5
77	Incidence of World Health Organization Stage 3 and 4 Events, Tuberculosis and Mortality in Untreated, HIV-infected Children Enrolling in Care Before 1 Year of Age. Pediatric Infectious Disease Journal, 2014, 33, 623-629.	2.0	23
78	Phase II Design With Sequential Testing of Hypotheses Within Each Stage. Journal of Biopharmaceutical Statistics, 2014, 24, 768-784.	0.8	0
79	Failure to Suppress Markers of Bone Turnover on First-Line Hormone Therapy for Metastatic Prostate Cancer Is Associated With Shorter Time to Skeletal-Related Event. Clinical Genitourinary Cancer, 2014, 12, 33-40.e4.	1.9	7
80	Progressive cerebral injury in the setting of chronic HIV infection and antiretroviral therapy. Journal of NeuroVirology, 2013, 19, 209-218.	2.1	71
81	Disrupted cerebral metabolite levels and lower nadir CD4+ counts are linked to brain volume deficits in 210 HIV-infected patients on stable treatmentpatients on stable treatment. NeuroImage: Clinical, 2013, 3, 132-142.	2.7	57
82	Outcomes of Antiretroviral Therapy in Children in Asia and Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 208-219.	2.1	81
83	A multi-index ROC-based methodology for high throughput experiments in gene discovery. International Journal of Data Mining and Bioinformatics, 2013, 8, 42.	0.1	2
84	Comparison of Methods for Correction of Mortality Estimates for Loss to Follow-Up after ART Initiation: A Case of the Infectious Diseases Institute, Uganda. PLoS ONE, 2013, 8, e83524.	2.5	21
85	Estimated mortality of adult HIV-infected patients starting treatment with combination antiretroviral therapy. Sexually Transmitted Infections, 2012, 88, i33-i43.	1.9	52
86	A Causal Framework for Understanding the Effect of Losses to Follow-up on Epidemiologic Analyses in Clinic-based Cohorts: The Case of HIV-infected Patients on Antiretroviral Therapy in Africa. American Journal of Epidemiology, 2012, 175, 1080-1087.	3.4	36
87	Retention in Care and Connection to Care among HIV-Infected Patients on Antiretroviral Therapy in Africa: Estimation via a Sampling-Based Approach. PLoS ONE, 2011, 6, e21797.	2.5	81
88	"Wamepotea"(They Have Become Lost): Outcomes of HIV-Positive and HIV-Exposed Children Lost to Follow-Up From a Large HIV Treatment Program in Western Kenya. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, e40-e46.	2.1	80
89	Trends in the clinical characteristics of HIV-infected patients initiating antiretroviral therapy in Kenya, Uganda and Tanzania between 2002 and 2009. Journal of the International AIDS Society, 2011, 14, 46.	3.0	43
90	Survival after Resection for Invasive Intraductal Papillary Mucinous Neoplasm and for Pancreatic Adenocarcinoma: A Multi-Institutional Comparison According to American Joint Committee on Cancer Stage. Journal of the American College of Surgeons, 2011, 213, 275-283.	0.5	66

#	Article	IF	Citations
91	Chemokines in cerebrospinal fluid correlate with cerebral metabolite patterns in HIV-infected individuals. Journal of NeuroVirology, 2011, 17, 63-69.	2.1	79
92	Alternative antiretroviral monitoring strategies for HIV‐infected patients in east Africa: opportunities to save more lives?. Journal of the International AIDS Society, 2011, 14, 38-38.	3.0	33
93	Universal Definition of Loss to Follow-Up in HIV Treatment Programs: A Statistical Analysis of 111 Facilities in Africa, Asia, and Latin America. PLoS Medicine, 2011, 8, e1001111.	8.4	167
94	Effects of nadir CD4 count and duration of human immunodeficiency virus infection on brain volumes in the highly active antiretroviral therapy era. Journal of NeuroVirology, 2010, 16, 25-32.	2.1	179
95	Cerebral metabolite abnormalities in human immunodeficiency virus are associated with cortical and subcortical volumes. Journal of NeuroVirology, 2010, 16, 435-444.	2.1	65
96	Retention in Care among HIV-Infected Patients in Resource-Limited Settings: Emerging Insights and New Directions. Current HIV/AIDS Reports, 2010, 7, 234-244.	3.1	234
97	Accuracy and cut‐off point selection in three‐class classification problems using a generalization of the Youden index. Statistics in Medicine, 2010, 29, 2946-2955.	1.6	83
98	Invasive intraductal papillary mucinous neoplasm: predictors of survival and role of adjuvant therapy. Hpb, 2010, 12, 447-455.	0.3	58
99	Tracking a sample of patients lost to follow‐up has a major impact on understanding determinants of survival in HIV‐infected patients on antiretroviral therapy in Africa. Tropical Medicine and International Health, 2010, 15, 63-69.	2.3	74
100	Retention of HIV‐infected and HIV‐exposed children in a comprehensive HIV clinical care programme in Western Kenya. Tropical Medicine and International Health, 2010, 15, 833-841.	2.3	54
101	Influence of gender on loss to follow-up in a large HIV treatment programme in western Kenya. Bulletin of the World Health Organization, 2010, 88, 681-688.	3.3	155
102	Adjusting Mortality for Loss to Follow-Up: Analysis of Five ART Programmes in Sub-Saharan Africa. PLoS ONE, 2010, 5, e14149.	2.5	85
103	Cardiac related death in thalassaemia major: time trend and risk factors in a large Greek Unit. European Journal of Haematology, 2009, 82, 381-387.	2.2	27
104	The OpenMRS Implementers Network. International Journal of Medical Informatics, 2009, 78, 711-720.	3.3	100
105	A comparison of tests for restricted orderings in the three‐class case. Statistics in Medicine, 2009, 28, 1144-1158.	1.6	16
106	Modeling AIDS survival after initiation of antiretroviral treatment by Weibull models with changepoints. Journal of the International AIDS Society, 2009, 12, 9-9.	3.0	13
107	The Need for Double‐Sampling Designs in Survival Studies: An Application to Monitor PEPFAR. Biometrics, 2009, 65, 301-306.	1.4	22
108	The impact of the President's Emergency Plan for AIDS Relief on expansion of HIV care services for adult patients in western Kenya. Aids, 2009, 23, 195-201.	2.2	29

#	Article	IF	Citations
109	The Clinical Burden of Tuberculosis Among Human Immunodeficiency Virus-Infected Children in Western Kenya and the Impact of Combination Antiretroviral Treatment. Pediatric Infectious Disease Journal, 2009, 28, 626-632.	2.0	48
110	Assessing multiple-group diagnostic problems with multi-dimensional receiver operating characteristic surfaces: Application to proton MR Spectroscopy (MRS) in HIV-related neurological injury. NeuroImage, 2008, 40, 248-255.	4.2	20
111	Relative sensitivity of magnetic resonance spectroscopy and quantitative magnetic resonance imaging to cognitive function among nondemented individuals infected with HIV. Journal of the International Neuropsychological Society, 2008, 14, 725-733.	1.8	73
112	Phase III Study of Cisplatin, Etoposide, and Concurrent Chest Radiation With or Without Consolidation Docetaxel in Patients With Inoperable Stage III Nonâ€"Small-Cell Lung Cancer: The Hoosier Oncology Group and U.S. Oncology. Journal of Clinical Oncology, 2008, 26, 5755-5760.	1.6	456
113	Sampling-Based Approaches to Improve Estimation of Mortality among Patient Dropouts: Experience from a Large PEPFAR-Funded Program in Western Kenya. PLoS ONE, 2008, 3, e3843.	2.5	73
114	Final Report of Toxicity and Efficacy of a Phase II Study of Oral Cyclophosphamide, Thalidomide, and Prednisone for Patients with Relapsed or Refractory Multiple Myeloma: A Hoosier Oncology Group Trial, HEM01â€"21. Oncologist, 2007, 12, 99-106.	3.7	52
115	Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo. Molecular Cancer Therapeutics, 2007, 6, 1736-1744.	4.1	39
116	Proton MRS and Neuropsychological Correlates in AIDS Dementia Complex: Evidence of Subcortical Specificity. Journal of Neuropsychiatry and Clinical Neurosciences, 2007, 19, 283-292.	1.8	75
117	Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. Aids, 2007, 21, 1877-1886.	2.2	141
118	Intraductal Papillary Mucinous Neoplasms. Annals of Surgery, 2007, 246, 644-654.	4.2	359
119	Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. Aids, 2006, 20, 41-48.	2.2	220
120	A sequential design to estimate sensitivity and specificity of a diagnostic or screening test. Statistics in Medicine, 2006, 25, 3458-3473.	1.6	6
121	A placebo-controlled study of memantine for the treatment of human immunodeficiency virusâ€"associated sensory neuropathy. Journal of NeuroVirology, 2006, 12, 328-331.	2.1	54
122	Excessive Toxicity When Treating Central Tumors in a Phase II Study of Stereotactic Body Radiation Therapy for Medically Inoperable Early-Stage Lung Cancer. Journal of Clinical Oncology, 2006, 24, 4833-4839.	1.6	1,406
123	Clinical validation of the NeuroScreen. Journal of NeuroVirology, 2005, 11, 503-511.	2.1	65
124	Intraperitoneal radioactive phosphorus (32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: a phase II Hoosier Oncology Group (HOG) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.4	25
125	A Phase II Multicenter, Randomized, Double-Blind, Safety Trial Assessing the Pharmacokinetics, Pharmacodynamics, and Efficacy of Oral 2-Methoxyestradiol Capsules in Hormone-Refractory Prostate Cancer. Clinical Cancer Research, 2005, 11, 6625-6633.	7.0	158
126	Weekly Paclitaxel and Gemcitabine in Advanced Transitional-Cell Carcinoma of the Urothelium: A Phase II Hoosier Oncology Group Study. Journal of Clinical Oncology, 2005, 23, 1185-1191.	1.6	97

#	Article	IF	Citations
127	Epigenetic Hypothesis Tests for Methylation and Acetylation in a Triple Microarray System. Journal of Computational Biology, 2005, 12, 370-390.	1.6	21
128	Outcome of Patients With Residual Germ Cell or Non-Germ Cell Malignancy After Resection of Primary Mediastinal Nonseminomatous Germ Cell Cancer. Journal of Clinical Oncology, 2004, 22, 1195-1200.	1.6	35
129	Phase II study of low-dose topotecan in myelodysplastic syndromes: a Hoosier Oncology Group (HOG) study. Leukemia Research, 2004, 28, 49-52.	0.8	6
130	Ordered multiple-class ROC analysis with continuous measurements. Statistics in Medicine, 2004, 23, 3437-3449.	1.6	202
131	Regional patterns of brain metabolites in AIDS dementia complex. NeuroImage, 2004, 23, 928-935.	4.2	87
132	A multi-center1H MRS study of the AIDS dementia complex: Validation and preliminary analysis. Journal of Magnetic Resonance Imaging, 2003, 17, 625-633.	3.4	88
133	Assessment of diagnostic markers by goodness-of-fit tests. Statistics in Medicine, 2003, 22, 2503-2513.	1.6	11
134	SDF-1Î± Is Expressed in Astrocytes and Neurons in the AIDS Dementia Complex: An In Vivo and In Vitro Study. Journal of Neuropathology and Experimental Neurology, 2003, 62, 617-626.	1.7	76
135	Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels. Aids, 2002, 16, 407-412.	2.2	81
136	Designs for clinical trials to test the efficacy of therapeutics in progressive multifocal leukoencephalopathy. Journal of NeuroVirology, 2001, 7, 369-374.	2.1	3
137	NF<i>K</i>B activation, TNF-Î± expression, and apoptosis in the AIDS-Dementia-Complex. Journal of NeuroVirology, 2000, 6, 537-543.	2.1	53
138	Refractory Mucosal Candidiasis in Advanced Human Immunodeficiency Virus Infection. Clinical Infectious Diseases, 2000, 30, 749-756.	5.8	93
139	Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. Aids, 1999, 13, 1677-1685.	2.2	131
140	Empirical bayes risk evaluation with type ii censored data. Journal of Statistical Computation and Simulation, 1993, 48, 195-206.	1.2	2
141	Neurologic Outcomes in HIV Infection: Clinical Events and Surrogate Markers. , 0, , 95-104.		0